Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
Authors
Keywords
-
Journal
Neurology-Neuroimmunology & Neuroinflammation
Volume 10, Issue 1, Pages e200056
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-11-22
DOI
10.1212/nxi.0000000000200056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B‐cell repopulation dynamics and drug pharmacokinetics impact SARS‐CoV ‐2 vaccine efficacy in anti‐CD20 ‐treated multiple sclerosis patients
- (2022) Klara Asplund Högelin et al. EUROPEAN JOURNAL OF NEUROLOGY
- Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
- (2021) Malin Boremalm et al. JOURNAL OF NEUROLOGY
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
- (2021) Amber Salter et al. JAMA Neurology
- Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
- (2021) Zoë YGJ van Lierop et al. Multiple Sclerosis Journal
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
- (2021) Sokratis A. Apostolidis et al. NATURE MEDICINE
- Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
- (2021) Leoni Rolfes et al. Neurology-Neuroimmunology & Neuroinflammation
- Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
- (2021) Klara Asplund Högelin et al. iScience
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
- (2021) Steve Simpson-Yap et al. NEUROLOGY
- Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis
- (2021) Irene Schiavetti et al. Multiple Sclerosis and Related Disorders
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
- (2020) Amit Bar-Or et al. NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules
- (2020) Benjamin P. Trewin et al. Multiple Sclerosis and Related Disorders
- Serious safety events in rituximab‐treated multiple sclerosis and related disorders
- (2020) Brandi L. Vollmer et al. Annals of Clinical and Translational Neurology
- Tailoring B cell depletion therapy in MS according to memory B cell monitoring
- (2020) Giovanni Novi et al. Neurology-Neuroimmunology & Neuroinflammation
- The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
- (2020) David Baker et al. Multiple Sclerosis and Related Disorders
- Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
- (2020) Neda Razaz et al. Neurology-Neuroimmunology & Neuroinflammation
- B cell depletion therapies in autoimmune disease: advances and mechanistic insights
- (2020) Dennis S. W. Lee et al. NATURE REVIEWS DRUG DISCOVERY
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
- (2019) Alexander Juto et al. Multiple Sclerosis and Related Disorders
- Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
- (2018) Ivan Jelcic et al. CELL
- Validation of the Swedish multiple sclerosis register
- (2018) P Alping et al. EPIDEMIOLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
- (2016) M. Vågberg et al. ACTA NEUROLOGICA SCANDINAVICA
- Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
- (2015) Rui Li et al. Science Translational Medicine
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
- (2012) Tom A. Barr et al. JOURNAL OF EXPERIMENTAL MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started